Navigation Links
Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits

s target of p<0.05), as previously reported. This was the second primary endpoint.

Implications of these additional data

The significantly reduced sedation seen with M6G provides additional support to our view that M6G is equivalent to morphine in controlling pain but has a superior side-effect profile. This should give clinicians more confidence that patients are less likely to experience sedation with M6G. Sedation is one of the side effects of most concern associated with agents like morphine, along with respiratory depression.

The additional analysis announced today will be used to improve further the designs of the planned US Phase III clinical studies by targeting higher risk patient groups and surgical procedures where the clinical benefits from M6G will be maximised.

Neil Clark, Chief Executive of CeNeS, commented: "This further analysis of the recent Phase III trial data supports our stated goal of delivering M6G to the market as a novel analgesic for post-operative pain that has clearly defined benefits compared to morphine and other opiates. The large body of statistically significant Phase III efficacy and side effect/safety data also suggest that M6G could be uniquely positioned as an opiate analgesic for day case surgery - an additional growing market to the current focus on hospital based post-operative pain.

"It is estimated that at least 277 million units of injectable analgesics were used to treat pain in the United States in 2006. The US post-operative pain market is estimated to be $1.7 billion. CeNeS is confident that M6G will establish a strong position in the large global pain market."

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising i
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
5. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
9. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
10. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
11. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
Post Your Comments:
(Date:12/15/2009)... Calif., Dec. 15 Dakim, Inc. and Alzheimer,s ... for Loved Ones, Brain Health Contest, designed to help ... of dementia and Alzheimer,s disease. All five winners will ... designed specifically to help seniors preserve their brain health ... in senior living communities across the country. ...
(Date:12/15/2009)... 15 Cumberland Pharmaceuticals Inc. ... new top-line results for a patient preference study ... a prescription laxative packaged as a crystalline powder, ... Kristalose is the only prescription-strength laxative available in ... patients with a recent diagnosis of chronic constipation ...
(Date:12/15/2009)... 15 Dynatronics Corporation (Nasdaq: ... preferred vendor agreement to provide therapy equipment and ... a nationwide network of physical, occupational and speech ... with Preferred Therapy Providers," said Larry K. Beardall, ... Dynatronics. "Their vast network of 1,100 clinics is ...
Breaking Medicine Technology:5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 25 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc. 2Hill Rom Holdings Inc Invites You to Join Its Fiscal 2009 Fourth Quarter Earnings and 2010 Financial Guidance Webcast 5793 1Hill Rom Holdings Inc Invites You to Join Its Fiscal 2009 Fourth Quarter Earnings and 2010 Financial Guidance Webcast 5793 2Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds 5789 1Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds 5789 2Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds 5789 3Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds 5789 4High definition colonoscopy detects more polyps Mayo Clinic researchers say 60250 1High definition colonoscopy detects more polyps Mayo Clinic researchers say 60250 2
... 16 Scientists announced today the,publication of a ... the,Bentham Open Stem Cell Journal which outlines the ... using autologous neural stem cells for the,treatment of ... MD, FRCS(C), FACS, "We have documented the first ...
... When treating children for acute osteomyelitis--a bacterial bone infection--an ... antibiotics is just as effective as continuing the IV ... drugs are more convenient for children and families, and ... of complications from using central catheters, such as infections ...
Other Medicine Technology:Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease 2Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease 3Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 2Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 3
(Date:12/16/2009)... offer free nationwide confidential legal consultations for users of Paxil ... Birth Defects, Attempted Suicide, Suicide and Addiction Issues. Individuals suffering ... or go to the firm’s website at http://www.ennislaw.com ... ... (PRWEB) December 16, 2009 -- Bloomberg ...
(Date:12/15/2009)... The failure of the U.S. Senate to allow ... less the more effective direct bulk purchasing of ... how big industry controls the health reform debate, ... by Senator Dorgan (D-ND) was a relatively modest ... allow Medicare to directly negotiate discounts with drug ...
(Date:12/15/2009)... Palo Alto Networks(TM), the network security company, today ... Series next-generation firewalls for accurate threat prevention on ... control over applications such as peer-to-peer file sharing. ... with eight facilities on five campuses. The university ... of academic schools and institutions throughout Japan. It ...
(Date:12/15/2009)... fell in area where all couples of reproductive age ... (HealthDay News) -- The number of children born with ... might be CF mutation carriers increases, a new study ... an area of northeast Italy for many years. Since ... decline in the number of infants born with CF. ...
(Date:12/15/2009)... but not delivered ,, WASHINGTON, Dec. 15 ... to ensure that healthcare reform does not override ... insurance companies in 37 states. ,, Prostate cancer ... the population and individuals who are identifiable as ... who have a family history of prostate cancer. ...
Breaking Medicine News(10 mins):Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 3Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 3Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis 2Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2
... A just-published research study by Dr. R Preston ... that astaxanthin, a relatively //unknown carotenoid found in ... for a new therapy to treat cardiovascular disease ... models. ,Combined with published proof-of-concept, pre-clinical and ...
... no one big way to reduce your risk for breast ... reports //the January 2007 issue of Harvard Women’s Health Watch. ... , Weight gain: Studies show that weight gain is ... is estrogen, which is believed to promote the development of ...
... can make a dramatic difference in the management of patients ... patients, a new study finds. // ,The study, ... of 35% of patients, said Philip W.P. Bearcroft, MD, of ... but more significant is the fact that before an MRI ...
... as well as widening the scope of its potential ... an instructional course at the recent American Academy of ... “LASIK in Eyes Following Previous Surgery: A Practical Approach ... Dr. Kanellopoulous, who was joined by Gregory Pamel, MD ...
... Meningitis scare has kept 20,000 children in three communities ... were closed on Thursday and Friday.// ,On ... Meningitis is the condition in which membranes protecting the ... the brain. Mycoplasma occasionally causes these neurological complications. ...
... posting of home video clips. All net lovers acclaimed it ... have put this novel invention to all possible uses. ... the website to get across health advice to patients. Last ... inhaler properly was launched in the website. ,Builth ...
Other Medicine News:Health News:Study Finds Astaxanthin Is Potent Inhibitor of Oxidation in Cell Membrane Model 2Health News:Study Finds Astaxanthin Is Potent Inhibitor of Oxidation in Cell Membrane Model 3Health News:Technology Making LASIK Safer for Those Who Have Had Previous Eye Surgery 2
Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
Used for emergency airway access when conventional endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
... steel. Lamp supplied with blade. Rusch ... quality standard incandescent laryngoscope blades. The ... continually refined through many years of ... maintenance requirements. They are manufactured to ...
... Snap-Light™ laryngoscope blades are designed with the ... optic bundle can be removed to simplify ... reach areas. Our unique snap-on mechanism eliminates ... focused blades are interchangeable with other green ...
Medicine Products: